<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05049044</url>
  </required_header>
  <id_info>
    <org_study_id>GFPC 06-2019</org_study_id>
    <nct_id>NCT05049044</nct_id>
  </id_info>
  <brief_title>Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC (OBSTINATE)</brief_title>
  <acronym>OBSTINATE</acronym>
  <official_title>Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC (OBSTINATE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Francais De Pneumo-Cancerologie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Francais De Pneumo-Cancerologie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBSTINATE is an observational, national, prospective, multicentric study on Quality of life&#xD;
      in patients with unresecable stade III non-small cell lung cancers.&#xD;
&#xD;
      Locally advanced non-small cell lung cancers (NSCLCs with a Tumor, Node and Metastasis [TNM]&#xD;
      stage III) patients represent approximately a third of newly discovered NSCLCs every year,&#xD;
      and a very heterogeneous group of clinical situations. Therapies are multidisciplinary and&#xD;
      very heterogeneous across oncology centers. Patients with locally advanced NSCLC have a high&#xD;
      symptom burden that is known to affect their quality of life. Health-related quality of life&#xD;
      (HR-QoL) is a specific and multidimensional type of patient-reported outcome (PRO) related to&#xD;
      the physical, psychological and social impact of the disease and its treatment as perceived&#xD;
      by patients. HR-QoL allows, together with data of efficacy and safety, a more complete&#xD;
      assessment of risks and benefits of each treatment. Therefore, QoL maintenance is a valuable&#xD;
      consideration for treatment decisions, especially in the rapidly evolving therapeutic&#xD;
      landscape of unresectable NSCLC.&#xD;
&#xD;
      The study is designed to collect PROs HR-QoL data from every new patient diagnosed with an&#xD;
      unresectable stage III NSCLC over a period of 18 months. We also aim to describe clinical&#xD;
      characteristics of these patients, the therapeutic strategies conducted, and outcomes in a&#xD;
      &quot;real-word&quot; oncological practice.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBSTINATE is an observational, prospective, national, multicentric study conducted in&#xD;
      patients newly diagnosed with an unresectable stage III NSCLC (with exclusion of early stages&#xD;
      NSCLC classified to pathological stage III).&#xD;
&#xD;
      OBSTINATE is a study planned to include 450 patients between 50 to 70 GFPC-affiliates or&#xD;
      GFPC-associated centers approximately. All centers are located in France. The participating&#xD;
      Site Investigators will be treating physicians within one of the participating centers.&#xD;
&#xD;
      After screening for eligibility checks, patients will receive the Patient Information Note&#xD;
      from the Site Investigators. This Patient information Note will describe the study purpose&#xD;
      and modalities. Patients who meet the eligibility criteria and do not oppose to data&#xD;
      collection will be enrolled. The schedule of the medical visits in the study center will&#xD;
      depend on the patient and his/her routine clinical care Protocol-relevant data will be&#xD;
      collected by the treating physician within each center, for up to 5 years following the last&#xD;
      patient's enrollment in the study.&#xD;
&#xD;
      Patients included in the study will complete the self-assess questionnaires at enrollment and&#xD;
      during routine care follow-up, according to pre-specified data collection schedule.&#xD;
&#xD;
      Usual practices or modalities of follow-up of patients will remain unchanged compared to the&#xD;
      current clinical practice as the study is designed to provide descriptive summary&#xD;
      information.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>QLQ-C30 (defined as the outcomes of a clinical intervention obtained by the patient)</measure>
    <time_frame>Up to 6,5 years (18 months of recruitment + 5 years). For Cohort 1 &amp; 2, a follow-up post progression is planned</time_frame>
    <description>Change in patient's QLQ-C30 during treatment and follow-up until confirmed progression, loss of follow-up or end of the study compared to Baseline in patients diagnosed with unresectable stage III NSCLC in a &quot;real-world&quot; oncological practice.&#xD;
This evaluation is based on self-assess questionnaire distributed to the patients according to pre-specified data collection schedule.&#xD;
The primary objective will be addressed in the cohort as a whole, and independently for every cohort of interest.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>QLQ-LC13 (defined as the outcomes of a clinical intervention obtained by the patient)</measure>
    <time_frame>Up to 6,5 years (18 months of recruitment + 5 years). For Cohort 1 &amp; 2, a follow-up post progression is planned</time_frame>
    <description>Change in patient's QLQ-LC13 during treatment and follow-up until confirmed progression, loss of follow-up or end of the study compared to Baseline in patients diagnosed with unresectable stage III NSCLC in a &quot;real-world&quot; oncological practice.&#xD;
This evaluation is based on self-assess questionnaire distributed to the patients according to pre-specified data collection schedule.&#xD;
The primary objective will be addressed in the cohort as a whole, and independently for every cohort of interest.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EQ5D-5L (defined as the outcomes of a clinical intervention obtained by the patient)</measure>
    <time_frame>Up to 6,5 years (18 months of recruitment + 5 years). For Cohort 1 &amp; 2, a follow-up post progression is planned</time_frame>
    <description>Change in patient's EQ5D-5L during treatment and follow-up until confirmed progression, loss of follow-up or end of the study compared to Baseline in patients diagnosed with unresectable stage III NSCLC in a &quot;real-world&quot; oncological practice.&#xD;
This evaluation is based on self-assess questionnaire distributed to the patients according to pre-specified data collection schedule.&#xD;
The primary objective will be addressed in the cohort as a whole, and independently for every cohort of interest.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline demographics</measure>
    <time_frame>At Baseline</time_frame>
    <description>Stage III unresectable NSCLC patients characteristics: baseline patient demographics at stage III NSCLC diagnosis, clinical, pathological and molecular characteristics (e.g. age, race, comorbidities)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor characteristics as defined by TNM stage</measure>
    <time_frame>At Baseline</time_frame>
    <description>Characterize the stage III unresectable NSCLC patients by TNM stage according to the 8th TNM IASLC edition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor characteristics as defined by PD-L1 expression status</measure>
    <time_frame>At Baseline</time_frame>
    <description>Characterize the stage III unresectable NSCLC patients by PD-L1 expression status (tumor propensity score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor characteristics as defined by mutational status of driver genes</measure>
    <time_frame>At Baseline</time_frame>
    <description>Characterize the stage III unresectable NSCLC patients by mutational status of driver genes (e.g. epidermal growth factor receptor [EGFR]) anaplastic lymphoma kinase [ALK], reactive oxygen species 1 [ROS1], human epidermal growth factor receptor 2 [HER2], PI3KCA, BRAF, MET, rearranged during transfection [RET], neurotrophic receptor tyrosine kinase [NRTK])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from diagnosis to treatment</measure>
    <time_frame>From date of diagnosis until the date of first documented treatment or start date of best supportive care through study completion, up to 5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modality of follow-up</measure>
    <time_frame>From date of diagnosis until the date of first documented progression or or date of death from any cause, whichever came first, assessed up to 5 years maximum</time_frame>
    <description>Description of modality of follow-up (e.g. type of imagery used, frequency of medical visit)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median PFS</measure>
    <time_frame>From date of first treatment administration up to first documented disease progression and/or death from any cause, whichever came first, assessed up to 60 months</time_frame>
    <description>Time from date of first treatment administration until the date of first documented progression or date to death from any cause, whichever came first as evaluated by investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median time to progression</measure>
    <time_frame>From date of first treatment administration up to first documented disease progression and/or death from any cause, whichever came first, assessed up to 60 months</time_frame>
    <description>Time from date of first treatment administration until the date of first documented progression or date to death from any cause, whichever came first as evaluated by investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median OS (e.g. median PFS, median OS)</measure>
    <time_frame>From date of first treatment administration up to first documented disease progression and/or death from any cause, whichever came first, assessed up to 60 months</time_frame>
    <description>Time from date of first treatment administration until the date of first documented progression or date to death from any cause, whichever came first as evaluated by investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment characteristics</measure>
    <time_frame>From date of first treatment administration up to end of study, assessed up to 5 years maximum</time_frame>
    <description>Describe the chemotherapy, radiation therapy and immunotherapy protocols used (e.g. dose, reduction, interruptions, duration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best response of treatment</measure>
    <time_frame>From date of first treatment administration up to end of study, assessed up to 5 years maximum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response of treatment</measure>
    <time_frame>From date of first treatment administration up to end of study, assessed up to 5 years maximum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of treatment</measure>
    <time_frame>From date of first treatment administration up to end of study, assessed up to 5 years maximum</time_frame>
    <description>limited to Cohorts 1, 2, 3 and 4 (restricted to significant AEs, which include but are not limited to: serious AEs [SAEs], AEs that led to treatment discontinuation, or any AEs ≥ grade 3 judged clinically significant by the Site Investigator)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective treatment compared to initial Multidisciplinary Tumor Board (MDTB) decision</measure>
    <time_frame>From date of first treatment administration up to end of study, assessed up to 5 years maximum</time_frame>
    <description>Concordance between effective treatment compared to initial MDTB decision</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of progression (local, loco-regional, metastatic)</measure>
    <time_frame>At date of first documented progression, assessed up to 5 years maximum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of second line of treatment after disease progression</measure>
    <time_frame>From date of first documented progression up to end of study, assessed up to 5 years maximum</time_frame>
    <description>Treatment characteristics after disease progression including type of treatment (chemotherapy, radiotherapy, immunotherapy or Tyrosine-Kinase inhibitors), treatment duration, stop date of treatment and reason for end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patients' socio-economic and occupational outcomes using unique self questionnaire</measure>
    <time_frame>From Baseline, during treatment and follow-up until confirmed progression (of note, for Cohorts 1 and 2, a follow-up post-progression is planned), loss of follow-up or end of the study, assessed up to 5 years maximum</time_frame>
    <description>Change in patients' socio-economic and occupational outcomes during treatment and follow-up until confirmed progression (of note, for Cohorts 1 and 2, a follow-up post-progression is planned), loss of follow-up or end of the study using a dedicated self questionnaire on socio-economic and occupational outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the cost-utility of the therapeutic strategy using Quality-Adjusted Life Years (QALYs)</measure>
    <time_frame>From Baseline, during treatment and follow-up until confirmed progression (of note, for Cohorts 1 and 2, a follow-up post-progression is planned), loss of follow-up or end of the study, assessed up to 5 years maximum</time_frame>
  </secondary_outcome>
  <number_of_groups>10</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1: cRT-CT+IO</arm_group_label>
    <description>Concomitant radio-chemotherapy and consolidation immunotherapy (cRT-CT+IO)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: sRT-CT+IO</arm_group_label>
    <description>Sequential radio-chemotherapy and consolidation immunotherapy (sRT-CT+IO)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: cRT-CT</arm_group_label>
    <description>Concomitant radio-chemotherapy (cRT-CT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: sRT-CT</arm_group_label>
    <description>Sequential radio-chemotherapy (sRT-CT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: CT</arm_group_label>
    <description>Chemotherapy only (CT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: CT+IO</arm_group_label>
    <description>Chemotherapy plus immunotherapy (CT+IO)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7: RT</arm_group_label>
    <description>Radiation therapy only (RT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8: IO</arm_group_label>
    <description>Immunotherapy only (IO)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9: TT</arm_group_label>
    <description>Targeted therapy only (TT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 10: BSC</arm_group_label>
    <description>Best supportive care only (BSC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality of Life Questionnaire-Core 30 (QLQ-C30)</intervention_name>
    <description>The HR-QoL evaluation is based on three self-assessment questionnaires distributed to the patients according to the pre-specified data collection schedule. Patients will also complete an additional questionnaire on socio-economic and occupational outcomes</description>
    <arm_group_label>Cohort 10: BSC</arm_group_label>
    <arm_group_label>Cohort 1: cRT-CT+IO</arm_group_label>
    <arm_group_label>Cohort 2: sRT-CT+IO</arm_group_label>
    <arm_group_label>Cohort 3: cRT-CT</arm_group_label>
    <arm_group_label>Cohort 4: sRT-CT</arm_group_label>
    <arm_group_label>Cohort 5: CT</arm_group_label>
    <arm_group_label>Cohort 6: CT+IO</arm_group_label>
    <arm_group_label>Cohort 7: RT</arm_group_label>
    <arm_group_label>Cohort 8: IO</arm_group_label>
    <arm_group_label>Cohort 9: TT</arm_group_label>
    <other_name>Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13)</other_name>
    <other_name>5-level EuroQoL EQ5D (EQ5D-5L)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Every new patients diagnosed with treatment-naïve unresectable stage III non-small cell&#xD;
        lung cancer (according to the 8th TNM IASLC edition).&#xD;
&#xD;
        Unresectability could be due to either functional limitation or anatomical extension of the&#xD;
        tumor.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathological confirmation of NSCLC obtained from a tumor cytology or biopsy&#xD;
&#xD;
          -  Treatment-naïve unresectable TNM stage III NSCLC (according to the 8th TNM IASLC&#xD;
             edition). Of note, unresectability could be due to either functional limitation or&#xD;
             anatomical extension of the tumor.&#xD;
&#xD;
          -  Patient willing and able to complete collection of data via self-assessment&#xD;
             questionnaires&#xD;
&#xD;
          -  Patient without any local or systemic anti-neoplastic treatment are eligible&#xD;
             (palliative symptomatic radiotherapy is considered best supportive care)&#xD;
&#xD;
          -  Patients participating in other interventional or non-interventional studies can be&#xD;
             included.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Early stage NSCLC initially treated locally (surgery or other) and classified as&#xD;
             pathological TNM stage III (according to the 8th TNM IASLC edition)&#xD;
&#xD;
          -  At the treating physician's discretion, patient not eligible physically or&#xD;
             psychologically to be included in a clinical trial&#xD;
&#xD;
          -  Inability to read and/or fill out self-assessment questionnaires&#xD;
&#xD;
          -  Patient unable to express opposition to data collection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles RICORDEL</last_name>
    <role>Principal Investigator</role>
    <affiliation>GFPC (Groupe Français de Pneumo-Cancérologie)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christos CHOUAID</last_name>
    <role>Study Director</role>
    <affiliation>GFPC (Groupe Français de Pneumo-Cancérologie)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charles RICORDEL</last_name>
    <phone>+33 (0) 2.99.28.37.38</phone>
    <phone_ext>87182</phone_ext>
    <email>Charles.RICORDEL@chu-rennes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sophie LECANUET</last_name>
    <phone>+33 (0)2 97 30 16 15</phone>
    <email>sophie.lecanuet.pro@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier d'Aix en Provence</name>
      <address>
        <city>Aix En Provence</city>
        <zip>13616</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie MARTINEZ</last_name>
      <email>smartinez@ch-aix.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphanie MARTINEZ</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Amiens-Picardie</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Géraldine FRANCOIS</last_name>
      <email>francois.geraldine@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Géraldine FRANCOIS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry URBAN</last_name>
      <phone>+33241355844</phone>
      <email>thurban@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry URBAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier d'Annecy</name>
      <address>
        <city>Annecy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chantal DECROISETTE</last_name>
      <email>cdecroisette@ch-annecygenevois.fr</email>
    </contact>
    <investigator>
      <last_name>Chantal H DECROISETTE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé d'Antony</name>
      <address>
        <city>Antony</city>
        <zip>92160</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier du Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles QUERE</last_name>
      <email>gilles.quere@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles QUERE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Paul d'Egine</name>
      <address>
        <city>Champigny-sur-Marne</city>
        <zip>94500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Chauny</name>
      <address>
        <city>Chauny</city>
        <zip>02300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick DUMONT</last_name>
      <email>patrick.dumont@ch-chauny.fr</email>
    </contact>
    <investigator>
      <last_name>Patrick DUMONT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier du Cotentin</name>
      <address>
        <city>Cherbourg</city>
        <zip>50102</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laure KALUZINSKI</last_name>
      <email>l.kaluzinski@ch-cotentin.fr</email>
    </contact>
    <investigator>
      <last_name>Laure KALUZINSKI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Créteil</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle MONNET</last_name>
      <email>isabelle.monnet@chicreteil.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle MONNET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier d'Elbeuf - Pneumologie</name>
      <address>
        <city>Elbeuf</city>
        <zip>76503</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Alexandre HAUSS</last_name>
      <email>Pierre-Alexandre.Hauss@chi-elbeuf-louviers.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre-Alexandre HAUSS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire DUPUYTREN</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain VERGNENEGRE</last_name>
      <phone>+33 5 55 05 66 29</phone>
      <email>alain.vergnenegre@unilim.fr</email>
    </contact>
    <investigator>
      <last_name>Alain VERGNENEGRE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital du Scorff</name>
      <address>
        <city>Lorient</city>
        <zip>56100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maud PEDRONO</last_name>
      <email>m.pedrono@ghps.bzh</email>
    </contact>
    <investigator>
      <last_name>Maud PEDRONO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen</name>
      <address>
        <city>Marseille</city>
        <zip>130003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques LE TREUT</last_name>
      <email>J.LETREUT@hopital-europeen.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques LE TREUT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent GREILLIER</last_name>
      <email>laurent.GREILLIER@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent GREILLIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de Meaux</name>
      <address>
        <city>Meaux</city>
        <zip>77100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional</name>
      <address>
        <city>Orléans</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hugues MOREL</last_name>
      <email>hugues.morel@chr-orleans.fr</email>
    </contact>
    <investigator>
      <last_name>Hugues MOREL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Catalan d'Oncologie</name>
      <address>
        <city>Perpignan</city>
        <zip>66000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine VEILLIOT</last_name>
      <email>sabinevieillot@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sabine VIEILLOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Quimper</name>
      <address>
        <city>Quimper</city>
        <zip>29000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romain CORRE</last_name>
      <phone>+33 (0)298100204</phone>
      <email>romain.corre@ch-cornouaille.fr</email>
    </contact>
    <investigator>
      <last_name>Romain CORRE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Ponchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles RICORDEL</last_name>
      <phone>+33299283738</phone>
      <email>Charles.RICORDEL@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian GUISIER</last_name>
      <email>florian.guisier@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Florian GUISIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU La Réunion Site Nord</name>
      <address>
        <city>Saint-Denis</city>
        <zip>97411</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane MOREAU</last_name>
      <email>diane.moreau@chu-reunion.fr</email>
    </contact>
    <investigator>
      <last_name>Diane MOREAU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU La Réunion Site Sud</name>
      <address>
        <city>Saint-Pierre</city>
        <zip>97410</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric HUCHOT</last_name>
      <email>eric.huchot@chr-reunion.fr</email>
    </contact>
    <investigator>
      <last_name>Eric HUCHOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre FOURNEL</last_name>
      <email>pierre.fournel@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre FOURNEL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital Nord</name>
      <address>
        <city>Saint-Étienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie BAYLE-BLEUEZ</last_name>
      <email>sophie.bayle@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie BAYLE-BLEUEZ</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Bigorre Tarbes</name>
      <address>
        <city>Tarbes</city>
        <zip>65013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axelle DEMAEGDT</last_name>
      <email>admaegdt@ch-tarbes-vic.fr</email>
    </contact>
    <investigator>
      <last_name>Axelle DEMAEGDT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Instruction des Armées Ste Anne</name>
      <address>
        <city>Toulon</city>
        <zip>83800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier BYLICKI</last_name>
      <email>bylicki.olivier@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier BYLICKI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Villefranche sur Saone</name>
      <address>
        <city>Villefranche Sur Saone</city>
        <zip>69655</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel FALCHERO</last_name>
      <phone>+33 4 74 09 27 23</phone>
      <email>LFalchero@lhopitalnordouest.fr</email>
    </contact>
    <investigator>
      <last_name>Lionel FALCHERO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 13, 2020</study_first_submitted>
  <study_first_submitted_qc>September 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Small-cell lung cancer</keyword>
  <keyword>Unresectable</keyword>
  <keyword>Advanced stage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

